

WaveLight AG: FDA approval for the ALLEGRETTO WAVE Eye-Q

High-quality product portfolio offers additional growth prospects in the U.S.A.

Erlangen, July 17, 2006. WaveLight AG, listed in Deutsche Börse AG's Prime Standard, has announced that its ALLEGRETTO WAVE Eye-Q excimer laser system for the correction of visual disorders today received the approval of the U.S. Food and Drug Administration (FDA). This means that the high-tech laser may now be sold with immediate effect in the U.S.A.

The ALLEGRETTO WAVE for the correction of visual disorders was the first European excimer laser to receive FDA approval in October 2003. Now its "big brother", the ALLEGRETTO WAVE Eye-Q, can also be used in U.S. clinics and practices with immediate effect. Like the ALLEGRETTO WAVE, the Eye-Q has also been approved for a wide range of treatments. For example, both laser systems can be used in refractive surgery not only for the precise correction of far- and nearsightedness, they also lend themselves to the effective treatment of astigmatism.

Around 100 ALLEGRETTO WAVE systems have already been installed in the U.S.A. since FDA approval was granted in October 2003. Thanks to its further enhanced design features, the newly approved ALLEGRETTO WAVE Eye-Q will enable WaveLight to increase its U.S. market penetration.

The ALLEGRETTO WAVE Eye-Q offers a large number of optimized treatment features. For example, the higher repetition rate (400 Hz) compared with the ALLEGRETTO WAVE significantly cuts treatment times even more, thus further reducing stress on both patients and physicians. An integrated cross line projector also increases treatment precision and rounds off the extended range of features offered by the ALLEGRETTO WAVE Eye-Q.

"The ALLEGRETTO WAVE Eye-Q extends our product range in the U.S.A. to include a technology-leading laser system, and opens up further growth and development potential in North America thanks to its optimized features," said Max Reindl, CEO of WaveLight AG.

WaveLight AG (ISIN DE 000 512 5603)

WaveLight AG, listed in Deutsche Börse AG's Prime Standard since January 2003, develops, produces, and markets a high-quality, end-to-end product portfolio in the fields of ophthalmology and aesthetics. WaveLight's market success is based on its innovative range of products that are the technology leaders in their areas of application and its broad-based sales network featuring both own sales channels and strategic partners. In the past fiscal year 2004/2005, WaveLight generated revenues of €80.7 million and EBIT of €8.8 million. Its average growth rate (CAGR) since 2000/2001 amounts to 35 percent for revenues and 63 percent for EBIT.

Further information on WaveLight is available at www.wavelight.com

Press Contacts:

Susanne Grethlein

WaveLight AG

Tel: + 49/9131/6186-103

Fax: + 49/9131/6186-112

E-mail: susanne.grethlein@wavelight.com

Gerhard Lodzwick

AGIL Gesellschaft für Finanzkommunikation mbH

Tel: +49/2131/12 55 73

Fax: +49/2131/12 557 55

E-mail: info@AGIL-IR.com

Disclaimer:

Some of the statements made in this disclosure take the form of forecasts or could be interpreted as such. All information is given and all assessments are made on the basis of extremely conscientious research. However, no guarantee is given with regard to the information or assessments published. No liability whatsoever is accepted. The above statements do not represent an invitation to buy or sell securities. All rights reserved.